Year: 2017
Type: article
Abstract: Neurodegenerative disorders are a major public health problem because of the high frequency of these diseases. Genome editing with the CRISPR/Cas9 system is making it possible to modify the sequence of genes linked to these disorders. We designed the KamiCas9 self-inactivating editing system to achieve transient expression of the Cas9 protein and high editing efficiency. In the first application, the gene responsible for Huntington's disease (HD) was targeted in adult mouse neuronal and glial cells. Mutant huntingtin (HTT) was efficiently inactivated in mouse models of HD, leading to an improvement in key markers of the disease. Sequencing of potential off-targets with the constitutive Cas9 system in differentiated human iPSC revealed a very low incidence with only one site above background level. This off-target frequency was significantly reduced with the KamiCas9 system. These results demonstrate the potential of the self-inactivating CRISPR/Cas9 editing for applications in the context of neurodegenerative diseases.
Source: Cell Reports
Authors: Nicolas Merienne, Gabriel Vachey, Lucie de Longprez, Cécile Meunier, Virginie Zimmer, Guillaume Perriard, Mathieu Canales, Amandine Mathias, Lucas Herrgott, Tim Beltraminelli, Axelle Maulet, Thomas Dequesne, Catherine Pythoud, Maria Rey, Luc Pellerin, Emmanuel Brouillet, Anselme L. Perrier, Renaud du Pasquier, Nicole Déglon
Institutions: Centre Hospitalier Universitaire Vaudois, Université Paris-Sud, Centre National de la Recherche Scientifique, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Université Paris-Saclay, Institut d'Imagerie Biomédicale, CEA Paris-Saclay - Etablissement de Fontenay-aux-roses, Direction de la Recherche Fondamentale, Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center, University of Lausanne, Inserm
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $5,025
Funders: National Science Foundation, Association Française contre les Myopathies, Novartis Foundation, EU Joint Programme – Neurodegenerative Disease Research, Animal Welfare Institute, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Fondation pour la Recherche Médicale, Université de Lausanne, Centre Hospitalier Universitaire Vaudois, Staatssekretariat für Bildung, Forschung und Innovation
Awards: G175125242, G2367388632, G2386236919, G5388495293, G544591541, G6498905070, ModifPolyQ - Advanced models of polyglutamine disorders (HD, SCA2, SCA3, SCA7), G7155227525, Infrastructure de Recherche Translationnelle pour les Biothérapies en Neurosciences, G8118032864, Gene editing for Huntington's disease, G8294286201, G941317200
OpenAlex ID: W2754902391
